The Searle Co (KAR:SEARL) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:SEARL The Searle Co Ltd KAR:SEARL
73 GF Score
Price ₨91.52
GF Value ₨76.13
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is The Searle Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

KAR:SEARL
73GF Score
The Searle Co Ltd KAR:SEARL
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is The Searle Co (KAR:SEARL) Overvalued in 2026?

Based on GuruFocus' analysis, The Searle Co stock appears to be overvalued. The current stock price of ₨91.52 is trading 20.2% above its estimated GF Value™ of ₨76.13. GuruFocus considers The Searle Co to be Modestly Overvalued.

Key valuation signals for KAR:SEARL:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: ₨76.13 vs. price of ₨91.52 (20.2% above fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the KAR:SEARL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

The Searle Co Business Description

Address Tipu Sultan Road, Block 7 and 8, Plot No. 1, One IBL Centre, 2nd Floor, D.M.C.H.S, Off Shahra-e-Faisal, Karachi, SD, PAK, 75530
The Searle Co Ltd is principally engaged in the manufacturing and sale of pharmaceutical, consumer health, and nutritional products. It manufactures and sells products such as Semavi, Dalimab, Extor, Tramal, Rotec, Hylixi, Emsyn, and many more, focusing on various therapeutic areas like cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care. Additionally, the group offers medical devices and disposables, health supplements, and various nutritional consumable products. The majority of the group's revenue consists of pharmaceutical sales. Geographically, it generates maximum revenue from Pakistan, and rest from Sri Lanka, Cambodia, Myanmar, Oman, Vietnam, and other countries.
73GF Score

Get the complete analysis for KAR:SEARL

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨91.52
Price
₨76.13
GF Value